Retatrutide appears to be a new medication in the fight against obesity. This groundbreaking drug, classified as a dual GLP-1 and GIP receptor agonist, exhibits promising results in investigations. By boosting these receptors, Retatrutide reduces hunger pangs, {promotesenergy expenditure, and ultima